Intravitreal bevacizumab in treatment of iris metastasis from primary lung carcinoma

BMJ Case Rep. 2019 Sep 8;12(9):e231097. doi: 10.1136/bcr-2019-231097.


Iris metastases secondary to primary malignancy are rare and usually have poor overall survival. We report a case of a man aged 60 years who presented with chief complaints of progressive pain and redness of right eye of 5 days duration. Slit-lamp examination revealed a greyish white irregular nodular mass, arising from anterior iris surface reaching up to mid-periphery. With a clinical suspicion of iris metastasis, systemic investigations were requested. CT scan of chest reported a well-defined lobulated lesion in the lower lobe of lung with presence of multiple satellite nodules in both lungs suggestive of primary malignant neoplasm of lung. Tissue diagnosis was obtained through an iris lesion biopsy, which was opted for relative ease of approach. Histopathology and immunohistochemistry confirmed the diagnosis of iris metastasis secondary to non-keratinising squamous cell carcinoma of lung. Local intravitreal injection of antivascular endothelial growth factor was administered for tumour regression along with systemic chemotherapy.

Keywords: Eye; Iris; Lung Cancer (oncology); Pathology.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents, Immunological / therapeutic use*
  • Bevacizumab / therapeutic use*
  • Carcinoma, Squamous Cell / drug therapy*
  • Carcinoma, Squamous Cell / secondary
  • Humans
  • Intravitreal Injections
  • Iris Neoplasms / drug therapy*
  • Iris Neoplasms / secondary
  • Lung Neoplasms / pathology*
  • Male
  • Middle Aged
  • Tomography, Optical Coherence


  • Antineoplastic Agents, Immunological
  • Bevacizumab